cognitive cybersecurity intelligence

News and Analysis

Search

Solvias to Perform Release Testing on CASGEVY

Solvias will provide analytical release testing services for the first genome-edited cell therapy, CASGEVY™, to treat sickle cell disease in patients aged 12 and older. The therapy has gained FDA approval and conditional approval from the EMA for severe sickle cell disease and transfusion-dependent beta thalassemia treatments.

Source: www.genengnews.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

How to Root Out Malicious Employees

Insider threats pose one of the largest security risks to organizations, and often go unnoticed or unaddressed. Malicious and negligent employees can commit devastating acts,